Drug intelligence / Profile preview

Orgibone

Development stage: Unknown
Lead developer: Allgems Healthcare
Modality: Small Molecules
Administration: Oral

Overview

Orgibone is an oral dietary supplement developed by Allgems Healthcare, specifically indicated for bone health and the prevention of osteoporosis. It is part of the company's nutraceutical portfolio. While the specific composition is not detailed in the available pipeline information, products in this category typically provide essential minerals and vitamins, such as calcium and vitamin D, to support bone mineral density and overall skeletal integrity. The product is currently approved and marketed for its intended use.

Brand names: Orgibone

Beyond the preview

Go deeper on Orgibone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orgibone.

Explore the full profile